Syros(SYRS) - 2023 Q2 - Earnings Call Presentation

| --- | |----------------------------------------------------------------------------------------------------------------------------------| | Novel oral form of arsenic trioxide (ATO) with opportunity to replace standard of care for APL patients | | Orally bioavailable with exposures consistent with IV ATO | | Clear development path to approval in frontline APL with potential to leverage emerging data for a more efficient pivotal study | | Potential for rapid adoption in frontline APL, benefitting from a s ...